AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Net sales decline while R&D investment surges
- Strategic use of IPO funds supports pivotal clinical trial
- Focus on scaling production for DurAVR® THV system
Anteris Technologies Global Corp. (ASX:AVR), a med-tech innovator now part of the broader ASX300 index, has released its financial and operational performance for the first quarter of fiscal 2025. Despite a dip in revenue, the company continues to press forward with key developmental initiatives aimed at its flagship product, the DurAVR® transcatheter heart valve (THV) system.
In Q1 2025, Anteris reported net sales of $0.6 million, marking a 27% decline from $0.8 million during the same period last year. The decline in revenue came alongside a 22% increase in operating losses, which reached $21.78 million compared to $17.78 million in Q1 2024. This broader loss reflects increased expenditures across research and clinical operations.
A significant portion of this increased spending was attributed to research and development, which rose by 42% to $16.46 million. This aligns with the company's focused efforts on progressing its clinical strategy, particularly the preparation and enrollment of its Pivotal Trial for DurAVR®.
Anteris is strategically deploying its $80 million in IPO proceeds to sustain momentum. Around $20.8 million has already been allocated to R&D for DurAVR® and the Pivotal Trial, with an additional $10.5 million directed toward working capital and general corporate purposes. This includes the repayment of $6.4 million in debt, reinforcing the company’s focus on financial health amid its growth strategy.
Operationally, the company is expanding its manufacturing footprint by establishing new ISO Qualified Clean Room facilities. These are intended to bolster the production capabilities for the DurAVR® system, essential for supporting both clinical trials and future commercialization. Additionally, Anteris is sourcing its proprietary ADAPT® tissue from the U.S. and Australia to strengthen supply chain resilience and meet increasing demands.
While the company does not currently fall under the list of traditional ASX dividend stocks, its presence in the S&P/ASX300 index places it within a cohort of companies that investors frequently monitor for long-term innovation and industry disruption.
As Anteris (AVR) doubles down on clinical and production infrastructure, its performance trajectory in the coming quarters will be one to watch, particularly for those tracking growth-focused healthcare innovators on the ASX.
